This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
RGS1 / Regulator of G-protein signaling 1 · Western blot design guide
Design a Western Blot for RGS1
Source-linked RGS1 Western blot protocol options, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-RGS1 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
RGS1 Western Blot Experimental Design Guide
Expected bands, source-linked protocol options, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~23.9 kDa | |
| Gel | 12–15% (standard starting point) | |
| Positive control | Bronchus (IHC candidate; verify WB) +4 more | |
| Negative control | Adipose tissue (IHC candidate; verify WB) |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | — | |
| Caveat | — | |
| Gene-set association | MSigDB Hallmark membership | |
| Isoform | 2 isoform(s) |
Section 1
Source-Linked RGS1 Western Blot Protocol Options
The A04483 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | Target-positive lysate and matched negative control (standard starting point) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Short semi-dry transfer; verify retention (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | A04483; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected RGS1 Western Blot Band Size?
RGS1 is predicted at 23.9 kDa; its two isoforms could affect migration, but no empirical band size or distinct isoform bands are demonstrated.
| Band near 23.9 kDa | Consistent with the predicted RGS1 mass; identity needs confirmation |
| Additional band at another size | Could reflect isoform 1 or 2 if they migrate differently; their sizes are unknown |
| Band in a membrane fraction | Consistent with RGS1 at the cytoplasmic side of the membrane |
| Band in a cytosolic fraction | Consistent with the reported cytosolic location of RGS1 |
💡Expected RGS1 appearanceRGS1 has a predicted mass of 23.9 kDa, but no empirical band size is supplied; confirm a candidate band with an independent antibody or RGS1 depletion.
| Predicted RGS1 mass | Places the reference band near 23.9 kDa |
| Splice isoform 1 | Its apparent size relative to isoform 2 is unknown |
| Splice isoform 2 | Its apparent size relative to isoform 1 is unknown |
| Alternative splicing | May alter apparent size, but distinct migration is unconfirmed |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | RGS1 may be scarce in the sampled cells or partition into an uncollected fraction | Check expression and examine membrane and cytosolic fractions |
| Band higher than expected | Its identity or migration is uncertain; no size-increasing modification is listed | Confirm with an independent antibody or RGS1 depletion |
| Band lower than expected | An isoform or degradation is possible, but neither band size is established | Check sample integrity and confirm the band with RGS1 depletion |
| Multiple bands | The two splice isoforms could contribute if they migrate differently | Compare bands after RGS1 depletion; assess isoform expression if needed |
| Weak or no signal | The sampled fraction may contain little RGS1 | Check expression and test membrane and cytosolic fractions |
Experiment evidence
Western blot images showing RGS1 band
A04483 · RGS1
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for RGS1 Western blot
🧪HPA-IHC candidate guidance (verify in WB): For positive controls for RGS1 in Western blot, you can use bronchus tissue, which has high HPA expression.
Positive control: Bronchus (IHC candidate; verify WB)
Negative control: Adipose tissue (IHC candidate; verify WB)
Loading controls: Run GAPDH, β-actin, and a total-protein stain such as Ponceau alongside the samples.
⚠️Feasibility: RGS1 is membrane-associated and cytosolic; verify that the HPA not-detected adipose tissue gives a low signal.
HPA tissue expression evidence for RGS1
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Bronchus | ciliated cells (ciliary rootlets) | High | Protein (IHC) | HPA → |
| Appendix | glandular cells | Medium | Protein (IHC) | HPA → |
| Bone marrow | hematopoietic cells | Medium | Protein (IHC) | HPA → |
| Breast | glandular cells | Medium | Protein (IHC) | HPA → |
| Caudate | neuronal cells | Medium | Protein (IHC) | HPA → |
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | adipocytes | Not detected | Protein (IHC) | HPA → |
| Cerebellum | cells in granular layer | Not detected | Protein (IHC) | HPA → |
| Heart muscle | cardiomyocytes | Not detected | Protein (IHC) | HPA → |
| Liver | cholangiocytes | Not detected | Protein (IHC) | HPA → |
| Ovary | follicle cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced RGS1 Western Blot Tips
Deeper troubleshooting and optimisation questions for RGS1, answered from its protein features.
Where should the RGS1 band appear relative to its predicted mass?
Band shift · Canonical RGS1 is 209 amino acids with a predicted mass of 23.9 kDa. No empirical apparent band position is supplied, so use 23.9 kDa as a reference rather than an expected exact position. The listed features alone cannot explain a difference between calculated and observed mass.
Could RGS1 isoforms produce different bands?
Isoforms · UniProt lists two isoforms. In isoform 2, canonical residues 149–209 are replaced by a shorter sequence, so the isoforms differ in length and C-terminal sequence. Check which isoform your antibody recognizes before assigning bands. Residue numbers here follow the supplied UniProt canonical sequence.
An antibody targeting canonical residues 149–209 may not recognize isoform 2, whose alternative sequence replaces that region. An epitope within residues 1–148 could potentially recognize both, depending on the antibody. Confirm the stated epitope and isoform coverage before comparing signals.
An antibody targeting canonical residues 149–209 may not recognize isoform 2, whose alternative sequence replaces that region. An epitope within residues 1–148 could potentially recognize both, depending on the antibody. Confirm the stated epitope and isoform coverage before comparing signals.
Do annotated modifications prove a band shift?
PTM · The linked UniProt record describes protein features. A modification annotation alone does not demonstrate a visible shift; retain any condition or experimental qualifier attached to it.
Does this guide establish induction of RGS1?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
What transfer method to use for RGS1 Western blot?
Transfer · RGS1 has a predicted mass of 23.9 kDa. Choose transfer conditions that retain proteins around this size, and check the post-transfer gel or membrane to confirm transfer. The supplied features do not identify a specific transfer method.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A04483 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should RGS1 be quantified?
Quantitation · Standard workflow guidance: quantify only a validated target band within the linear exposure range. Use consistent sample preparation and loading, retain biological replicates, and avoid interpreting saturation or loading differences as regulation.
Should RGS1 be measured in membrane or cytosolic fractions?
Interpretation · RGS1 is reported at the cytoplasmic side of the cell membrane as a peripheral membrane protein and in the cytosol. Consider both fractions when assessing its distribution; a weak signal in one fraction alone does not establish low total RGS1 abundance.
Keep the analyzed fraction consistent across samples because RGS1 is reported in both membrane-associated and cytosolic locations. If resolving multiple bands, establish which isoform each represents before combining their intensities. The supplied features do not establish that either isoform produces a distinct visible band.
First consider isoform recognition: isoform 2 replaces canonical residues 149–209 with a shorter sequence. Check the antibody epitope and whether the band appears in membrane-associated or cytosolic material. The supplied features list no modified residues or glycosylation sites, and they do not establish a cause for any observed band shift.
Keep the analyzed fraction consistent across samples because RGS1 is reported in both membrane-associated and cytosolic locations. If resolving multiple bands, establish which isoform each represents before combining their intensities. The supplied features do not establish that either isoform produces a distinct visible band.
First consider isoform recognition: isoform 2 replaces canonical residues 149–209 with a shorter sequence. Check the antibody epitope and whether the band appears in membrane-associated or cytosolic material. The supplied features list no modified residues or glycosylation sites, and they do not establish a cause for any observed band shift.
Boster reagents
RGS1 Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-RGS1 Antibody
Cat # A04483
A04483 is an anti-RGS1 polyclonal antibody listed for Western blotting, with reported reactivity to human, mouse, and rat. A WB image is provided, but the supplied excerpt does not identify the tested cells or full conditions.
Which to pick: A04483 is the only listed RGS1 antibody and has a WB validation image. Check that its listed human, mouse, or rat reactivity matches your sample; the supplied excerpt does not specify which cells were tested.
Source: BosterBio RGS1 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry Q08116.
- Human Protein Atlas. RGS1 tissue expression.
- PMC12358342 — target-verified WB comparison
- PMC9310486 — target-verified WB comparison
- PMC11006993 — target-verified WB comparison